Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 29% Improvement Relative Risk Mahale et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 134 patients in India (March - May 2020) Lower mortality with HCQ (not stat. sig., p=0.36) Mahale et al., Indian J. Critical Care Medicine, doi:10.5005/jp-journals-10071-23599 Favors HCQ Favors control
A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital
Mahale et al., Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-23599
Mahale et al., A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a.., Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-23599
Dec 2020   Source   PDF  
  All Studies   Meta
Retrospective 134 hospitalized COVID-19 patients in India, showing no significant difference with HCQ treatment in unadjusted results.
Although the 29% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [18‑27%] from meta analysis of the 232 mortality results to date. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 28.7% lower, RR 0.71, p = 0.36, treatment 25 of 102 (24.5%), control 11 of 32 (34.4%), NNT 10.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mahale et al., 31 Dec 2020, retrospective, India, peer-reviewed, 22 authors, study period 22 March, 2020 - 21 May, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: RESEARCH ARTICLE A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital Nilesh Mahale1, Prasad Rajhans2, Purushotham Godavarthy3, Vikram L Narasimhan4, Gauri Oak5, Srinath Marreddy6, Amruta Bedekar7, Ujwal Dhundi8, Harshwardhan S Pawar9, Prasad Akole10, Balasaheb Pawar11, Bhagyashri Bhurke12, Shailaja Chavan13, Parikshit Prayag14, Bharat Purandare15, Pradip Dalvi16, Vishnu Telbhare17, Prasanna Marudwar18, Dnyaneshwar Diwane19, Manasi Shahane20, Amrita Prayag21, Shradha Gugale22, Shreyas Bhor23, Sameer Jog24 A b s t r ac t​ Objectives: To describe the demographics and evaluate the clinical outcomes of hypoxic coronavirus disease-2019 (COVID-19) patients treated with different immunomodulatory (IM) drugs in a resource-limited setting. Materials and methods: We conducted a retrospective cohort study of these patients admitted to our hospital between March 22 and May 31, 2020. Data were abstracted from multiple electronic data sources or patient charts to provide information on patient characteristics, clinical, laboratory variables, and outcomes. Results: A total of 134 patients met the inclusion criteria and were followed up till June 7, 2020. The median age of the patients was 55.6 years (range 20–89 years) and 68% were men. At least one comorbidity was seen in 72% of the patients with diabetes (44%) and hypertension (46%) being the most common. At triage, fever (82%), shortness of breath (77%), and cough (61%) were the most common presenting symptoms. A PaO2/FiO2 ratio less than 300 was seen in 60%, and 4.5% required invasive mechanical ventilation within 72 hours of hospital admission. Five immunomodulatory agents (hydroxychloroquine, methylprednisolone, colchicine, etoricoxib, and tocilizumab) were administered in different combinations. Overall, in-hospital mortality was 26.9%, and 32% required mechanical ventilation. Around 69% of patients were discharged home. Five variables (SpO2, PaO2/FiO2 ratio, leukocytosis, lymphopenia, and creatinine) on admission were found to be significant in the patients who died. Conclusion: Our study provides the characteristics and outcomes of hypoxic COVID-19 patients treated with IM drugs in varied combination. Five independent variables were strong predictors of mortality. Keywords: Acute respiratory distress syndrome, Coronavirus disease-2019, Immunomodulatory drugs, Resource-limited settings. Indian Journal of Critical Care Medicine (2020): 10.5005/jp-journals-10071-23599 I n t r o d u c t i o n​ India reported the first case of coronavirus disease-2019 (COVID19) on January 30, 2020.1 The World Health Organization (WHO) declared COVID-19 as pandemic on March 11, 2020, and our hospital admitted the first COVID patient on March 22. Though the exact pathogenesis of severe acute respiratory syndrome-coronavirus-2 (SARS CoV-2) is unknown, various hypotheses have proposed cytokine storm or hyperinflammatory syndrome as probable causes for rapid worsening of the disease. To date, there is no evidence that any potential therapy improves outcomes in patients with COVID192–4 and various antiviral and immunomodulatory (IM) drugs have been repurposed for the treatment of COVID-19. Currently, there is no published data about baseline characteristics, clinical features, and outcomes from India. Considering the impact the disease has on the public health especially in a resource-limited country like ours, we conducted a retrospective..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop